Avrobio (NASDAQ:AVRO) announced its earnings results on Thursday. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.02, Fidelity Earnings reports.
AVRO traded up $0.84 during trading on Friday, hitting $15.39. The company had a trading volume of 122,200 shares, compared to its average volume of 225,991. The company has a market cap of $349.17 million, a PE ratio of -4.25 and a beta of 2.63. The business has a 50-day moving average of $14.77 and a 200-day moving average of $17.14. Avrobio has a 1-year low of $11.85 and a 1-year high of $31.00.
Several research analysts have recently weighed in on AVRO shares. Wedbush restated an “outperform” rating and issued a $43.00 target price on shares of Avrobio in a research note on Friday, August 9th. Mizuho restated a “buy” rating and issued a $28.00 target price on shares of Avrobio in a research note on Sunday, August 11th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Avrobio in a research note on Friday. Cowen restated a “buy” rating on shares of Avrobio in a research note on Monday, July 15th. Finally, Zacks Investment Research raised shares of Avrobio from a “sell” rating to a “hold” rating in a report on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $28.92.
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Read More: What is Liquidity?
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.